» Articles » PMID: 27358439

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap

Overview
Journal Circulation
Date 2016 Jul 1
PMID 27358439
Citations 414
Authors
Affiliations
Soon will be listed here.
Abstract

Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF with reduced EF, large trials testing neurohumoral inhibition in HFpEF failed to reach a positive outcome. This failure was recently attributed to distinct systemic and myocardial signaling in HFpEF and to diversity of HFpEF phenotypes. In this review, an HFpEF treatment strategy is proposed that addresses HFpEF-specific signaling and phenotypic diversity. In HFpEF, extracardiac comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency drive left ventricular remodeling and dysfunction through systemic inflammation and coronary microvascular endothelial dysfunction. The latter affects left ventricular diastolic dysfunction through macrophage infiltration, resulting in interstitial fibrosis, and through altered paracrine signaling to cardiomyocytes, which become hypertrophied and stiff because of low nitric oxide and cyclic guanosine monophosphate. Systemic inflammation also affects other organs such as lungs, skeletal muscle, and kidneys, leading, respectively, to pulmonary hypertension, muscle weakness, and sodium retention. Individual steps of these signaling cascades can be targeted by specific interventions: metabolic risk by caloric restriction, systemic inflammation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors, muscle weakness by exercise training, sodium retention by diuretics and monitoring devices, myocardial nitric oxide bioavailability by inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content by neprilysin or phosphodiesterase 9 inhibition, and myocardial fibrosis by spironolactone. Because of phenotypic diversity in HFpEF, personalized therapeutic strategies are proposed, which are configured in a matrix with HFpEF presentations in the abscissa and HFpEF predispositions in the ordinate.

Citing Articles

HFpEF correlated with better improvement of left atrial function in post-ablation patients with paroxysmal atrial fibrillation.

Sun K, Qin X, Zhang D, Fang F, Wan R, Wang J Int J Cardiovasc Imaging. 2025; .

PMID: 40025277 DOI: 10.1007/s10554-025-03359-0.


Does Adiponectin Inform Cardiovascular Risk in Older Adults?: The ARIC Study.

Abushamat L, Jia X, Xu L, Cheng C, Ndumele C, Sun C JACC Adv. 2025; 4(3):101625.

PMID: 39983616 PMC: 11891717. DOI: 10.1016/j.jacadv.2025.101625.


Identification of digital twins to guide interpretable AI for diagnosis and prognosis in heart failure.

Gu F, Meyer A, Jezek F, Zhang S, Catalan T, Miller A NPJ Digit Med. 2025; 8(1):110.

PMID: 39966509 PMC: 11836287. DOI: 10.1038/s41746-025-01501-9.


The Protocol for the Multi-Ethnic, multi-centre raNdomised controlled trial of a low-energy Diet for improving functional status in heart failure with Preserved ejection fraction (AMEND Preserved).

Bilak J, Squire I, Wormleighton J, Brown R, Hadjiconstantinou M, Robertson N BMJ Open. 2025; 15(1):e094722.

PMID: 39880434 PMC: 11781100. DOI: 10.1136/bmjopen-2024-094722.


High-resolution DNA methylation changes reveal biomarkers of heart failure with preserved ejection fraction versus reduced ejection fraction.

Benincasa G, Pepin M, Russo V, Cacciatore F, DAlto M, Argiento P Basic Res Cardiol. 2024; .

PMID: 39725721 DOI: 10.1007/s00395-024-01093-7.


References
1.
Yusuf S, Pfeffer M, Swedberg K, Granger C, Held P, McMurray J . Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362(9386):777-81. DOI: 10.1016/S0140-6736(03)14285-7. View

2.
Takimoto E, Champion H, Li M, Belardi D, Ren S, Rodriguez E . Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005; 11(2):214-22. DOI: 10.1038/nm1175. View

3.
Fukuta H, Sane D, Brucks S, Little W . Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation. 2005; 112(3):357-63. DOI: 10.1161/CIRCULATIONAHA.104.519876. View

4.
Huang P, Leu H, Chen J, Wu T, Lu T, Ding Y . Comparison of endothelial vasodilator function, inflammatory markers, and N-terminal pro-brain natriuretic peptide in patients with or without chronotropic incompetence to exercise test. Heart. 2005; 92(5):609-14. PMC: 1860951. DOI: 10.1136/hrt.2005.064147. View

5.
Sanderson J . Heart failure with a normal ejection fraction. Heart. 2006; 93(2):155-8. PMC: 1861394. DOI: 10.1136/hrt.2005.074187. View